Evaluation of a Novel Molecular NSCLC Classification System
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Validation of a novel 4-protein signature's ability to subtype NSCLC
研究概览
简要总结
This research studies protein in tumor samples from patients with non-small cell lung cancer. Finding specific proteins in tumor tissue samples from patients with cancer may help doctors tell what type of lung cancer a patient has and plan better treatment.
详细描述
PRIMARY OBJECTIVES:
I. To validate a novel 4-protein signature's ability to subtype non-small cell lung cancer (NSCLC) in a treatment-naive, multi-institutional cohort, Cancer and Leukemia Group B (CALGB) 9761.
SECONDARY OBJECTIVES:
I. To estimate the NSCLC misclassification rate in a multi-institutional clinical-trial setting for stage 1 NSCLC (adenocarcinoma versus squamous cell).
OUTLINE:
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have been registered on CALGB-9761
- •Stage I disease
- •Treatment-naive patients
- •A representative paraffin block of the primary tumor must be available from patients on CALGB-9761 and submitted to the CALGB Pathology Coordinating Office
- •A separate consent form is not required for this study, as permission for research to be performed on the tissue blocks is included in the consent form for CALGB 9761
- •Institutional review board (IRB) review and approval at the institution where the laboratory work will be performed is required
排除标准
- 未提供
结局指标
主要结局
Validation of a novel 4-protein signature's ability to subtype NSCLC
时间窗: 1 month
次要结局
- NSCLC misclassification rate(1 month)
